Startup Deep Dive : Wysa — an FDA breakthrough device on Rs 47 crore of revenue

A chatbot with no human on the other end has passed a threshold few digital health products ever reach: an FDA Breakthrough Device Designation, granted in May 2022 for an AI-led conversational tool treating chronic pain, depression and anxiety together. Yet the company that built it, Wysa, closed its most recent disclosed financial year — FY25, ending 31 March 2025 — on revenue of just ₹47.31 crore (roughly $4.9 million at $1 ≈ ₹96.0, 18 September 2026, Trading Economics).

That gap — a regulatory nod usually reserved for medical devices, sitting on top of a business smaller than a mid-sized Indian retail chain’s monthly sales — is the real story here. Wysa did not start as a chatbot at all. It took four product pivots, a founder’s own depression, and roughly 800 iterations before the company found the one thing that worked: a listener that never gets tired, never judges, and remembers nothing when you close the app.

Quick facts

What they do

Wysa sells access to an AI chatbot, built around cognitive behavioural therapy (CBT) techniques, that talks people through anxiety, low mood and stress, and can route them to a human coach or therapist when needed. It sells this in two ways at once: as a free, anonymous consumer app that anyone can download, and, increasingly, as a licensed benefit that employers, health insurers and health systems buy on behalf of their employees, members or patients. By the company’s own published figures, it has been used by more than six million people across roughly 95 countries through upwards of 500 million AI-led conversations (company-stated, Wysa Reports page, wysa.com).

The origin

Jo Aggarwal and Ramakant Vempati are a husband-and-wife team who left corporate jobs in the UK — Aggarwal at Pearson Learning Solutions, Vempati at Goldman Sachs International — and moved back to India in 2012 to look after family. Their first venture was Touchkin, incorporated on 19 January 2015 in Bengaluru, which used passive smartphone sensing — how someone types, moves and sleeps, read off phone sensors rather than self-reports — to flag signs of depression in family caregiving contexts. In early clinical testing the sensing model reportedly reached 90% accuracy at detecting depressive symptoms, according to Aggarwal’s own account (The Politic, interview published March 2018).

The insight that eventually became Wysa was not a new algorithm. It was a realisation about trust: people would rather tell an anonymous AI what they are feeling than have an app silently infer it from their phone usage and report it to someone else. That shift — from passive surveillance to something a person actively, anonymously confides in — is what turned a failing caregiving tool into a mental health product with a very different audience.

The struggle years

Touchkin’s caregiving app did not find a paying market. Aggarwal has described pouring marketing spend into user acquisition without a path to sustainability, calling the experience “a bottomless pit,” and has said the strain tipped her into her own burnout and depression while still running the company (The Politic, March 2018). She has said she then taught herself cognitive behavioural therapy to manage her own symptoms, and it was that experience — realising CBT is a learnable skill, not only a clinical treatment administered by a professional — that reframed what the product should be.

Getting there was not a single clean pivot. By the company’s own account, Wysa went through four major product changes and close to 800 iterations, built and discarded through direct listening to early users, before the anonymous chatbot format stuck (YourStory company profile). The Wysa app itself launched in 2016, a side project inside the still-struggling Touchkin, at a point when the company had no evidence yet that a chatbot — as opposed to sensor-based monitoring — was the more fundable, more usable idea.

The turning point

The clearest before-and-after in Wysa’s history sits around its FDA Breakthrough Device Designation, granted in May 2022 for an AI-led conversational agent treating adults with chronic musculoskeletal pain alongside depression and anxiety (Healio, 13 May 2022; Wysa company blog, May 2022). The designation followed a peer-reviewed study published in JMIR Human Factors on 27 April 2022, which tracked 2,194 Wysa users who reported chronic pain. In the subsamples measured on standard clinical scales, mean depression scores (PHQ-9) fell from 13.22 to 10.03, and mean anxiety scores (GAD-7) fell from 12.02 to 9.04, both statistically significant changes (P<.001) with a medium effect size.

The numbers either side of that moment are stark. Before the designation, Wysa was one AI wellness app among a crowded field competing largely on app-store downloads. Two months after the FDA news, in July 2022, Wysa closed a $20 million Series B — at the time its largest round by a wide margin, more than triple its total funding raised up to that point. A regulatory signal built on a specific, published clinical result, not a broader growth metric, is what investors backed.

The money behind it

• Seed, March 2016: $400,000 from angel investors, the company’s first institutional capital.
• Seed, July 2017: $1.3 million led by Kae Capital, with angel participation (Business Standard, 29 July 2017).
• Pre-Series A, June 2019: approximately $2 million led by pi Ventures, with Kae Capital participating (Business Standard, 20 June 2019).
• Series A, May 2021: $5.5 million led by W Health Ventures, a Boston-based digital health investor, with Google Assistant Investments, pi Ventures and Kae Capital participating (TechCrunch; BusinessToday, 21 May 2021).
• Series B, July 2022: $20 million led by HealthQuad, with British International Investment (BII) — the UK government’s development finance institution — joining for the first time (TechCrunch; YourStory; MobiHealthNews, 14 July 2022).
• Grant, May 2023: an additional, amount-undisclosed grant from Zurich Insurance Group, per Inc42’s funding tracker.

Two backers changed the company’s trajectory in documented ways. W Health Ventures’ Series A cheque was explicitly earmarked to build out Wysa’s employer and health-plan sales motion in the US, according to the company’s own funding announcement. HealthQuad’s Series B, with BII alongside it, funded expansion into the US, UK and India simultaneously and pushed Wysa toward regulated, clinically-validated products rather than a pure wellness app — the same period in which the FDA designation and NHS deployments landed. Total funding raised stood at more than $34 million across eight rounds as of Inc42’s May 2023 tracker; the company has not disclosed a post-Series B valuation from a primary source, so no specific figure is used here.

How it makes money

• Enterprise and health-system contracts: employers, health insurers and health systems license Wysa as a covered benefit for employees, members or patients. Named clients disclosed by the company and reported in the trade press include Accenture, Colgate-Palmolive, Aetna International, Swiss Re, the NHS in the UK, Cincinnati Children’s Hospital Medical Center and Singapore’s Ministry of Health (TechCrunch, July 2022).
• Consumer freemium app: a free, anonymous chatbot available directly to individuals, which also functions as a funnel and proof point for the enterprise sales conversation.
• NHS-embedded referral tool: rather than a standalone consumer sale, Wysa has been built directly into NHS Talking Therapies referral and clinical-record workflows — including an integration with Mayden’s iaptus care-record system — putting the product in front of patients before they see a therapist, across more than 30 NHS Talking Therapies services.

Wysa does not publish its per-contract pricing or the exact split of revenue between enterprise licensing and consumer subscriptions, so no percentage figure is used here. What outside coverage and the client list consistently point to is that enterprise and health-system contracts, not app-store subscriptions, are the commercial core — the part a first-time user of the free app is unlikely to realise, since nothing in that experience signals that a corporate or NHS contract, not their own wallet, is what pays for the product.

The numbers

Revenue for FY20 and FY21 is as reported by Entrackr (14 July 2022), citing the company’s own filings; FY25 revenue and its 18.0% growth rate are as reported by TheCompanyCheck, an MCA-filings aggregator. Filings for FY22 and FY23 were not accessible for independent verification at the time of writing, and are left out rather than estimated; the FY24 figure shown is simple arithmetic on the disclosed FY25 growth rate, not a separately filed number, and is labelled accordingly. FY25 profit or loss was not available without a paid data subscription and is not reported here.

Where the money comes from

• North America: enterprise employer and insurer contracts, including Accenture, Colgate-Palmolive and Aetna International (company-stated, via TechCrunch, July 2022).
• Europe: the NHS in the UK, where Wysa is deployed across more than 30 NHS Talking Therapies services and was the first AI mental health app to meet the NHS’s DCB 0129 clinical safety standard (Wysa/NHS coverage, 2022–2023).
• Asia-Pacific: government and enterprise contracts including Singapore’s Ministry of Health, alongside the company’s origins and part of its team based in India.

The surprise is where the growth is not coming from. Wysa’s biggest publicised user number — more than six million people, roughly 95 countries — is a consumer-app metric. But the contracts named in its own funding announcements and press coverage are almost entirely institutional: insurers, employers, hospital systems and a national health service, not individual app-store subscribers. A large free user base functions here mainly as a sales credential and a data source for clinical publications, rather than as a direct line to revenue.

The risks

• Narrow regulatory scope: the FDA Breakthrough Device Designation applies only to one specific indication — an AI-led CBT tool for adults with chronic musculoskeletal pain alongside depression and anxiety — and is not a blanket clearance for Wysa’s other products (Healio, 13 May 2022). Full FDA market clearance for that indication still requires further regulatory steps that could be delayed or fail.
• Disclosed AI-safety limitations: Wysa’s own clinical-programme materials state that AI is “developing technology where potential risks may not be fully understood” and that users may sometimes receive responses that do not reflect the correct action needed — a company-disclosed risk for a product whose core function is responding to people in emotional distress.
• Category fragility and customer concentration: revenue depends on renewing a relatively small number of enterprise and health-system contracts rather than a broad base of paying consumers, at a company with FY25 revenue of only ₹47.31 crore ($4.9 million). The category’s fragility is visible elsewhere too: rival consumer mental-health chatbot Woebot shut down its consumer app entirely on 30 June 2025, even after a widely cited 2017 clinical trial of its own.

The takeaway

Wysa’s founders did not arrive at a chatbot because they set out to build one. They arrived at it after a caregiving app built on passive phone-sensing failed to find buyers, after roughly 800 discarded iterations, and after the founder’s own depression taught her that what people wanted was not to be monitored but to be heard, anonymously, without consequence. The lesson that travels beyond mental health tech is about the nature of the pivot itself: the fix for a product that will not find product-market fit is sometimes not a better algorithm or more marketing spend, but a change in what the user is being asked to trust the product with. Wysa’s technology — conversational AI trained on CBT technique — existed in an earlier, failed form too. What changed was the relationship on offer.

Frequently asked questions

What does Wysa do?

Wysa is an AI chatbot built on cognitive behavioural therapy techniques that helps people manage anxiety, low mood and stress, with an option to connect to a human coach or therapist. It is sold both as a free consumer app and as a licensed benefit that employers, insurers and health systems provide to employees, members or patients.

Who founded Wysa, and when?

Jo Aggarwal and Ramakant Vempati founded the company as Touchkin, incorporated on 19 January 2015 in Bengaluru, before pivoting to the Wysa chatbot, which launched in 2016.

How much funding has Wysa raised, and from whom?

Wysa has raised more than $34 million across eight disclosed rounds as of May 2023, per Inc42’s funding tracker, including a $5.5 million Series A in May 2021 led by W Health Ventures and a $20 million Series B in July 2022 led by HealthQuad with British International Investment. Other backers include Kae Capital, pi Ventures and Google Assistant Investments.

Is Wysa FDA-approved?

Not fully. In May 2022, Wysa received FDA Breakthrough Device Designation, which fast-tracks regulatory review, specifically for an AI-led conversational tool addressing chronic musculoskeletal pain with depression and anxiety. That is narrower than full market clearance and does not apply to Wysa’s other products.

How does Wysa make money if the app is free to download?

The free consumer app functions mainly as a funnel and a clinical-evidence base. The disclosed commercial core is enterprise and health-system licensing — contracts with employers, insurers and health systems such as Accenture, Aetna International, Swiss Re and the NHS in the UK — rather than individual consumer subscriptions.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• The Politic, “An Interview with Jo Aggarwal, Co-inventor of Wysa,” March 2018
• YourStory, Wysa company profile
• Business Standard, “Wysa raises $1.3 mn in seed funding,” July 2017
• Business Standard, “pi Ventures, Kae Capital back AI-based mental health start-up Wysa,” June 2019
• BusinessToday, “Google backed mental health startup Wysa raises $5.5 mn in Series A funding,” 21 May 2021
• TechCrunch, “Mental health app Wysa raises $5.5M for emotionally intelligent AI,” May 2021
• TechCrunch, “Wysa $20 million Series B funding to expand therapist chatbot, wider mental health services,” 14 July 2022
• YourStory, “Wysa raises $20M from HealthQuad, British International Investment,” July 2022
• MobiHealthNews, “Mental health chatbot Wysa raises $20M,” July 2022
• Wysa company blog (blogs.wysa.io), “Wysa Secures $20m to Address Global Mental Health Demand With AI Digital Therapeutics,” July 2022
• Inc42, Wysa funding tracker (company/wysa/funding), accessed September 2026, funding data through May 2023
• Entrackr, “Wysa raises $20 Mn in Series B round,” 14 July 2022 (FY20/FY21 revenue and FY21 loss figures)
• TheCompanyCheck, Touchkin eServices Private Limited company profile (FY25 revenue and incorporation/director details), accessed September 2026
• Healio, “FDA designates AI-based therapy for pain, depression, anxiety as breakthrough device,” 13 May 2022
• Wysa company blog, “Wysa Receives FDA Breakthrough Device Designation for AI-Led Mental Health Conversational Agent,” May 2022
• JMIR Human Factors, “Understanding People With Chronic Pain Who Use a Cognitive Behavioral Therapy-Based Artificial Intelligence Mental Health App (Wysa): Mixed Methods Retrospective Observational Study,” 27 April 2022
• Wysa, “Wysa AI Support for NHS Talking Therapies” and clinical-evidence pages (wysa.com), accessed September 2026
• Wysa Reports page (wysa.com/reports), company-stated user and conversation figures, accessed September 2026
• buildmvpfast.com, “Mental Health AI Chatbots: Clinical Evidence for Woebot & Wysa,” 2026 (Woebot consumer app closure, 30 June 2025)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.